Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

作者：Chloe Orkin, Enrique Bernal, Darrell H. S. Tan, Harold Katner, Hans‐Jürgen Stellbrink, Elena Belonosova, Rebecca DeMoor, Sandy Griffith, Shanker Thiagarajah, Rodica Van Solingen‐Ristea, Susan L. Ford, Herta Crauwels, Parul Patel, Amy Cutrell, Kimberly Y. Smith, Kati Vandermeulen, Eileen Birmingham, Marty St. Clair, William Spreen, Ronald D’Amico · 发表于：The Lancet HIV · 年份：2021 · DOI：10.1016/s2352-3018(21)00184-3 · 被引用次数：143 · 研究领域：HIV-related health complications and treatments、HIV Research and Treatment、HIV/AIDS drug development and treatment